- 专利标题： ERK inhibitor and use thereof
-
申请号： US16973335申请日： 2019-06-06
-
公开(公告)号： US11466013B2公开(公告)日： 2022-10-11
- 发明人: Hao Wu , Wei Gu , Xiaojing Tang , Wei Wang , Bo Zhan , Dongjie Feng , Yongxin Ke , Zhongyan Chen , Yifei Shen , Wenmao Wu , Xintao Zhao , Hong Lan , Jiabing Wang , Lieming Ding
- 申请人： Betta Pharmaceuticals Co., LTD
- 申请人地址： CN Zhejiang
- 专利权人： Betta Pharmaceuticals Co., LTD
- 当前专利权人： Betta Pharmaceuticals Co., LTD
- 当前专利权人地址： CN Zhejiang
- 代理机构： Umberg Zipser LLP
- 代理商 Jason Tejani
- 优先权： WOPCT/CN2018/090385 20180608,WOPCT/CN2018/120975 20181213
- 国际申请： PCT/CN2019/090221 WO 20190606
- 国际公布： WO2019/233457 WO 20191212
- 主分类号： C07D487/04
- IPC分类号： C07D487/04 ; A61P35/00 ; C07D401/04 ; C07D403/14 ; C07D417/04 ; C07D487/20 ; C07D491/20 ; C07D513/04 ; C07D519/00
摘要：
Disclosed are a compound (as shown in formula I) as an extracellular signal-regulated kinase (ERK) inhibitor, a pharmaceutical composition thereof, a preparation method therefor, and use thereof in treating ERK-mediated diseases. Said compound plays a role by regulating a plurality of processes such as cell proliferation, apoptosis, migration and angiogenesis.
公开/授权文献
- US20210261552A1 ERK INHIBITOR AND USE THEREOF 公开/授权日：2021-08-26
信息查询
